Amarin Corporation

Amarin Corporation Net Debt per Share

The Net Debt per Share of Amarin Corporation (AMRN) as of Nov 19, 2026 is -14.01 USD. In the previous year, Net Debt per Share was -13.81 USD — a change of 1.44% (lower).

Net Debt per Share

-14.01USD

YoY

1.44%

Last updated:

Net Debt per Share of Amarin Corporation is 2025 -14.01 USD. Net Debt per Share of Amarin Corporation was 2024 -13.81 USD. It decreases by 1.44% lower compared to the previous year.

The Amarin Corporation Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-8.14 USD
Jan 1, 2019
-28.19 USD
Jan 1, 2020
-23.70 USD
Jan 1, 2021
-21.47 USD
Jan 1, 2022
-14.43 USD
Jan 1, 2023
-15.03 USD
Jan 1, 2024
-13.81 USD
Jan 1, 2025
-14.01 USD
The Amarin Corporation Net Debt per Share history
YEARNet Debt per ShareYoY
-14.01USD+1.44%
-13.81USD-8.15%
-15.03USD+4.20%
-14.43USD-32.81%
-21.47USD-9.40%
-23.70USD-15.94%
-28.19USD+246.41%
-8.14USD-444.52%
2.36USD+169.34%
0.88USD-87.38%
6.95USD+34.36%
5.17USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Net Debt per Share of Amarin Corporation is -14.01 USD in 2025.

Net Debt per Share of Amarin Corporation changed from -13.81 USD to -14.01 USD, representing a 1.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Amarin Corporation

All Key Metrics — Amarin Corporation